Rich countries are opening up societies and vaccinating young people who are not at great risk from Covid-19, while the poorest countries cruelly lack doses, the World Health Organization said on ...

As the country scrambles to curb the spread of Covid-19, we will be entering yet another lockdown. The current infection rate stands at 23.86 percent, with specific regions crumbling under surmounting ...

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. This stock is a ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...

Moderna has rallied ~23%, but I maintain a 'Sell' and 'market underperform' rating due to deteriorating fundamentals. MRNA’s recent rally is driven by improved liquidity, cost discipline, and a $1.5 ...

Dec 18 (Reuters) - Moderna (MRNA.O), opens new tab will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S.

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups could help fill the void after the Trump administration slashed federal ...

This year’s flu season is shaping up to be a nasty one—driven by a new variant of the influenza virus that may be able to slip past our vaccine defenses. A mutated form of the influenza A strain H3N2 ...

Long COVID is best understood as a collection of overlapping symptoms rather than a single post-viral condition, suggests a ...

Norovirus, the highly contagious stomach bug that causes vomiting and diarrhea, is surging again. Here's what to expect and ...